Which has better earnings & valuation, VCYT or TWST?

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 9.33 $66.35M $1.09 55.50 Twist Bioscience $376.57M 16.51 -$77.67M -$1.33 N/A

Does the media favor VCYT or TWST?

In the previous week, Twist Bioscience had 5 more articles in the media than Veracyte. MarketBeat recorded 13 mentions for Twist Bioscience and 8 mentions for Veracyte. Veracyte's average media sentiment score of 0.54 beat Twist Bioscience's score of 0.13 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TWST or INSM more profitable?

Twist Bioscience has a net margin of -19.85% compared to Insmed's net margin of -144.44%. Twist Bioscience's return on equity of -26.73% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Twist Bioscience -19.85% -26.73% -19.15% Insmed -144.44% -130.11% -51.57%

Does the media prefer TWST or INSM?

In the previous week, Insmed had 7 more articles in the media than Twist Bioscience. MarketBeat recorded 20 mentions for Insmed and 13 mentions for Twist Bioscience. Insmed's average media sentiment score of 0.89 beat Twist Bioscience's score of 0.13 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TWST or VTRS more profitable?

Viatris has a net margin of -2.04% compared to Twist Bioscience's net margin of -19.85%. Viatris' return on equity of 19.04% beat Twist Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Twist Bioscience -19.85% -26.73% -19.15% Viatris -2.04% 19.04% 7.62%

Does the media prefer TWST or VTRS?

In the previous week, Twist Bioscience had 10 more articles in the media than Viatris. MarketBeat recorded 13 mentions for Twist Bioscience and 3 mentions for Viatris. Viatris' average media sentiment score of 0.56 beat Twist Bioscience's score of 0.13 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, TWST or GMAB?

Genmab A/S has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $376.57M 16.51 -$77.67M -$1.33 N/A Genmab A/S $3.72B 4.38 $963M $1.32 19.78

Does the media prefer TWST or GMAB?

In the previous week, Twist Bioscience had 5 more articles in the media than Genmab A/S. MarketBeat recorded 13 mentions for Twist Bioscience and 8 mentions for Genmab A/S. Twist Bioscience's average media sentiment score of 0.13 beat Genmab A/S's score of -0.19 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TWST or ASND?

In the previous week, Twist Bioscience had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Twist Bioscience and 11 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.54 beat Twist Bioscience's score of 0.13 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Twist Bioscience (TWST) Competitors

$99.84 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$98.00 -1.84 (-1.84%)

As of 06/26/2026 07:55 PM Eastern

Compare

TWST vs. VCYT, INSM, VTRS, GMAB, and ASND

Should you buy Twist Bioscience stock or one of its competitors? MarketBeat compares Twist Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Twist Bioscience include Veracyte (VCYT), Insmed (INSM), Viatris (VTRS), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.

How does Twist Bioscience compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Veracyte presently has a consensus target price of $47.57, indicating a potential downside of 21.36%. Twist Bioscience has a consensus target price of $74.60, indicating a potential downside of 25.28%. Given Veracyte's higher possible upside, analysts clearly believe Veracyte is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Veracyte has a net margin of 16.25% compared to Twist Bioscience's net margin of -19.85%. Veracyte's return on equity of 9.07% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Veracyte has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

In the previous week, Twist Bioscience had 5 more articles in the media than Veracyte. MarketBeat recorded 13 mentions for Twist Bioscience and 8 mentions for Veracyte. Veracyte's average media sentiment score of 0.54 beat Twist Bioscience's score of 0.13 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	9.33	$66.35M	$1.09	55.50
Twist Bioscience	$376.57M	16.51	-$77.67M	-$1.33	N/A

Summary

Veracyte beats Twist Bioscience on 10 of the 15 factors compared between the two stocks.

How does Twist Bioscience compare to Insmed?

Twist Bioscience (NASDAQ:TWST) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, Insmed had 7 more articles in the media than Twist Bioscience. MarketBeat recorded 20 mentions for Insmed and 13 mentions for Twist Bioscience. Insmed's average media sentiment score of 0.89 beat Twist Bioscience's score of 0.13 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Twist Bioscience has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Twist Bioscience currently has a consensus price target of $74.60, suggesting a potential downside of 25.28%. Insmed has a consensus price target of $211.86, suggesting a potential upside of 104.94%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Twist Bioscience has a net margin of -19.85% compared to Insmed's net margin of -144.44%. Twist Bioscience's return on equity of -26.73% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Insmed	-144.44%	-130.11%	-51.57%

Twist Bioscience has higher earnings, but lower revenue than Insmed. Twist Bioscience is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	16.51	-$77.67M	-$1.33	N/A
Insmed	$606.42M	36.95	-$1.28B	-$5.75	N/A

Summary

Insmed beats Twist Bioscience on 9 of the 15 factors compared between the two stocks.

How does Twist Bioscience compare to Viatris?

Twist Bioscience (NASDAQ:TWST) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Twist Bioscience has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Twist Bioscience has higher earnings, but lower revenue than Viatris. Twist Bioscience is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	16.51	-$77.67M	-$1.33	N/A
Viatris	$14.30B	1.33	-$3.51B	-$0.26	N/A

In the previous week, Twist Bioscience had 10 more articles in the media than Viatris. MarketBeat recorded 13 mentions for Twist Bioscience and 3 mentions for Viatris. Viatris' average media sentiment score of 0.56 beat Twist Bioscience's score of 0.13 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris has a net margin of -2.04% compared to Twist Bioscience's net margin of -19.85%. Viatris' return on equity of 19.04% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Viatris	-2.04%	19.04%	7.62%

Twist Bioscience currently has a consensus target price of $74.60, suggesting a potential downside of 25.28%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 7.16%. Given Viatris' higher probable upside, analysts clearly believe Viatris is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Viatris beats Twist Bioscience on 9 of the 16 factors compared between the two stocks.

How does Twist Bioscience compare to Genmab A/S?

Twist Bioscience (NASDAQ:TWST) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Twist Bioscience had 5 more articles in the media than Genmab A/S. MarketBeat recorded 13 mentions for Twist Bioscience and 8 mentions for Genmab A/S. Twist Bioscience's average media sentiment score of 0.13 beat Genmab A/S's score of -0.19 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.1% of Genmab A/S shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Genmab A/S has a net margin of 21.05% compared to Twist Bioscience's net margin of -19.85%. Genmab A/S's return on equity of 15.34% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Genmab A/S	21.05%	15.34%	8.94%

Twist Bioscience has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Twist Bioscience presently has a consensus price target of $74.60, suggesting a potential downside of 25.28%. Genmab A/S has a consensus price target of $37.93, suggesting a potential upside of 45.29%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Genmab A/S has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	16.51	-$77.67M	-$1.33	N/A
Genmab A/S	$3.72B	4.38	$963M	$1.32	19.78

Summary

Genmab A/S beats Twist Bioscience on 10 of the 17 factors compared between the two stocks.

How does Twist Bioscience compare to Ascendis Pharma A/S?

Twist Bioscience (NASDAQ:TWST) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Ascendis Pharma A/S has a net margin of 57.87% compared to Twist Bioscience's net margin of -19.85%. Ascendis Pharma A/S's return on equity of 0.00% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Twist Bioscience currently has a consensus target price of $74.60, indicating a potential downside of 25.28%. Ascendis Pharma A/S has a consensus target price of $295.39, indicating a potential upside of 13.28%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Twist Bioscience has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Twist Bioscience has higher earnings, but lower revenue than Ascendis Pharma A/S. Twist Bioscience is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	16.51	-$77.67M	-$1.33	N/A
Ascendis Pharma A/S	$814.57M	19.97	-$258M	$8.67	30.07

In the previous week, Twist Bioscience had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Twist Bioscience and 11 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.54 beat Twist Bioscience's score of 0.13 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Twist Bioscience on 12 of the 15 factors compared between the two stocks.

Get Twist Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TWST vs. The Competition

Export

Metric	Twist Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.22B	$3.63B	$7.03B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-75.07	21.56	26.13	24.16
Price / Sales	16.51	334.26	555.66	102.83
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	12.73	8.31	10.78	6.38
Net Income	-$77.67M	$23.92M	$3.58B	$337.00M
7 Day Performance	17.22%	1.93%	1.97%	-0.20%
1 Month Performance	49.30%	-0.41%	-0.24%	-1.40%
1 Year Performance	177.87%	65.22%	34.39%	27.76%

Twist Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TWST Twist Bioscience	1.3744 of 5 stars	$99.84 flat	$74.60 -25.3%	+177.9%	$6.22B	$376.57M	N/A	990	News Coverage Analyst Forecast Insider Trade High Trading Volume
VCYT Veracyte	1.5973 of 5 stars	$53.19 -0.8%	$47.57 -10.6%	+120.9%	$4.28B	$517.15M	48.80	790	Analyst Forecast
INSM Insmed	3.5562 of 5 stars	$98.61 +2.9%	$211.86 +114.9%	+3.9%	$20.76B	$606.42M	N/A	1,664	News Coverage Insider Trade
VTRS Viatris	2.6275 of 5 stars	$15.38 +0.1%	$17.50 +13.8%	+81.2%	$17.90B	$14.30B	N/A	30,000	Insider Trade
GMAB Genmab A/S	4.6648 of 5 stars	$25.61 +1.3%	$37.93 +48.1%	+27.3%	$15.76B	$3.72B	19.40	3,029	Analyst Forecast Options Volume Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TWST) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Twist Bioscience (TWST) Competitors

TWST vs. VCYT, INSM, VTRS, GMAB, and ASND

How does Twist Bioscience compare to Veracyte?

Summary

How does Twist Bioscience compare to Insmed?

Summary

How does Twist Bioscience compare to Viatris?

Summary

How does Twist Bioscience compare to Genmab A/S?

Summary

How does Twist Bioscience compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Twist Bioscience (TWST) Competitors

TWST vs. VCYT, INSM, VTRS, GMAB, and ASND

How does Twist Bioscience compare to Veracyte?

Do analysts rate VCYT or TWST?

Is VCYT or TWST more profitable?

Which has more risk and volatility, VCYT or TWST?

Does the media favor VCYT or TWST?

Which has better earnings & valuation, VCYT or TWST?

Summary

How does Twist Bioscience compare to Insmed?

Does the media prefer TWST or INSM?

Which has more volatility and risk, TWST or INSM?

Do analysts prefer TWST or INSM?

Is TWST or INSM more profitable?

Which has better valuation & earnings, TWST or INSM?

Summary

How does Twist Bioscience compare to Viatris?

Which has more risk and volatility, TWST or VTRS?

Do insiders and institutionals hold more shares of TWST or VTRS?

Which has stronger earnings and valuation, TWST or VTRS?

Does the media prefer TWST or VTRS?

Is TWST or VTRS more profitable?

Do analysts prefer TWST or VTRS?

Summary

How does Twist Bioscience compare to Genmab A/S?

Does the media prefer TWST or GMAB?

Do institutionals & insiders hold more shares of TWST or GMAB?

Is TWST or GMAB more profitable?

Which has more volatility and risk, TWST or GMAB?

Do analysts prefer TWST or GMAB?

Which has better valuation and earnings, TWST or GMAB?

Summary

How does Twist Bioscience compare to Ascendis Pharma A/S?

Is TWST or ASND more profitable?

Do analysts rate TWST or ASND?

Which has more risk & volatility, TWST or ASND?

Which has better valuation and earnings, TWST or ASND?

Does the media refer more to TWST or ASND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TWST vs. The Competition

Twist Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools